← Ablatotech Vitals
Ophthalmology EvidenceDigest

CRISPR-Cas9 Applications in Treating Hereditary Eye Disorders

Ophthalmology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 1, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

CRISPR-Cas9 genome editing holds significant promise for treating hereditary eye disorders by enabling precise correction of pathogenic mutations in retinal cells. Early preclinical studies demonstrate successful gene correction and functional restoration in models of inherited retinal dystrophies such as Leber congenital amaurosis (LCA). However, clinical translation faces challenges including delivery efficiency, off-target effects, and immune responses. Continued refinement of CRISPR technologies and delivery methods is essential before widespread clinical application can be realized (DiCarlo et al., 2018; Zhang et al., 2025).

Clinical bottom line

CRISPR-Cas9 genome editing holds significant promise for treating hereditary eye disorders by enabling precise correction of pathogenic mutations in retinal cells. Early preclinical studies demonstrate successful gene correction and functional restoration in models of inherited retinal dystrophies such as Leber congenital amaurosis (LCA). However, clinical translation faces challenges including delivery efficiency, off-target effects, and immune responses. Continued refinement of CRISPR technologies and delivery methods is essential before widespread clinical application can be realized (DiCarlo et al., 2018; Zhang et al., 2025).

What the evidence shows

DiCarlo et al. (2018) provide foundational insights into gene therapy and genome surgery in the retina, illustrating that CRISPR-Cas9 can be used to edit disease-causing mutations in retinal pigment epithelium and photoreceptors with restoration of visual function in animal models.

Zhang et al. (2025) review advancements in precision medicine for LCA, highlighting CRISPR-based approaches that have corrected mutations in CEP290 and other genes, with emerging clinical trials exploring safety and efficacy.

Botto et al. (2021) discuss progress in gene editing tools, emphasizing CRISPR-Cas9’s versatility and potential to correct mutations underlying vision loss, while noting challenges such as delivery vectors and minimizing off-target editing.

Varapula et al. (2021) and Pop-Bica et al. (2021) outline CRISPR-Cas9 principles and applications, underscoring its adaptability for ophthalmic genetic disorders and the importance of optimizing genome mapping and sequencing to guide precise editing.

María Vaschetto Luis et al. (2021) further elaborate on CRISPR-based genome editing strategies, including base editing and prime editing, which may enhance safety and precision in ocular gene therapy.

Caveats and uncertainty

Most data derive from preclinical models; human clinical trial data remain limited.

Efficient and safe delivery of CRISPR components to retinal cells is a major hurdle, with viral and nonviral vectors under investigation.

Off-target cleavage and unintended genomic alterations pose safety concerns.

Immune responses to CRISPR-associated proteins may limit efficacy or cause adverse effects.

Long-term durability of gene correction and functional outcomes require further study.

Ethical and regulatory considerations around germline editing and irreversible changes remain unresolved.

How this may change practice

CRISPR-Cas9 could revolutionize treatment of hereditary eye diseases by providing durable, potentially curative therapies targeting the root genetic cause.

Ophthalmologists may increasingly collaborate with geneticists and molecular specialists to identify candidates for gene editing interventions.

Integration of advanced genomic diagnostics will be critical to tailor CRISPR-based therapies.

As clinical trials mature, CRISPR therapies may complement or replace existing gene augmentation or pharmacologic treatments.

Careful patient counseling regarding benefits, risks, and uncertainties will be essential.


References

  1. DiCarlo JE, et al. Gene therapy and genome surgery in the retina. J Clin Invest. 2018; DOI:10.1172/JCI120429
  2. Zhang P, et al. The advancements in precision medicine for Leber congenital amaurosis: Breakthroughs from genetic diagnosis to therapy. Surv Ophthalmol. 2025; DOI:10.1016/j.survophthal.2025.04.005
  3. Botto C, et al. Progress in gene editing tools and their potential for correcting mutations underlying hearing and vision loss. Front Genome Ed. 2021; DOI:10.3389/fgeed.2021.737632
  4. Varapula D, et al. Recent applications of CRISPR-Cas9 in genome mapping and sequencing. CRISPR/Cas9 Based Genome Editing for Treating Genetic Disorders and Diseases. 2021; DOI:10.1201/9781003088516-2
  5. Pop-Bica C, et al. The CRISPR/Cas9 genome-editing system: Principles and applications. CRISPR/Cas9 Based Genome Editing for Treating Genetic Disorders and Diseases. 2021; DOI:10.1201/9781003088516-1
  6. María Vaschetto L, et al. CRISPR/Cas9 based genome editing for treating genetic disorders and diseases. 2021; DOI:10.1201/9781003088516

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team